泰德医药(03880)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

03880 泰德医药

已收盘 10-14 16:00:00

21.320

+0.300

+1.43%

最高21.480	最低20.740	成交量7.34万
今开21.120	昨收21.020	日振幅3.52%
总市值30.23亿	流通市值30.23亿	总股本1.42亿
成交额153.82万	换手率0.05%	流通股本1.42亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"03880","market":"HK","secType":"STK","nameCN":"泰德医药","latestPrice":21.32,"timestamp":1791964800011,"preClose":21.02,"halted":0,"volume":73400,"delay":0,"changeRate":0.014272121788772631,"floatShares":141800000,"shares":141800000,"eps":1.9113591486289216,"marketStatus":"已收盘","change":0.3,"latestTime":"10-14 16:00:00","open":21.12,"high":21.48,"low":20.74,"amount":1538232,"amplitude":0.035205,"askPrice":21.34,"askSize":400,"bidPrice":20.72,"bidSize":100,"shortable":0,"etf":0,"ttmEps":1.3964894163461987,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1792027800000},"marketStatusCode":5,"adr":0,"listingDate":1751212800000,"exchange":"SEHK","adjPreClose":21.02,"openAndCloseTimeList":[[1791941400000,1791950400000],[1791954000000,1791964800000]],"volumeRatio":1.018596,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/03880/tweets","defaultTab":"tweets","newsList":[{"id":"1118278762","title":"泰德医药9月未有新增发行或股份变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1118278762","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1118278762?lang=zh_cn&edition=full","pubTime":"2026-10-06 17:07","pubTimestamp":1791277636,"startTime":"0","endTime":"0","summary":"泰德医药（浙江）股份有限公司于2026年10月6日发布截至2026年9月30日的证券变动月报表。报告期内，公司注册地为中国境内，“法定股本”概念不适用；本次披露的为已发行股本的变动情况。与上一个月末相比，本期无新增发行、购回或注销股份，公司库藏股数目亦为零。公司在月报中披露，报告期内并无股权激励或期权计划的变化，亦无任何可转换债券或其他股份发行安排。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03880"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669465745","title":"泰德医药：收购工业用地作为规模化多肽CDMO生产基地","url":"https://stock-news.laohu8.com/highlight/detail?id=2669465745","media":"财中社","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669465745?lang=zh_cn&edition=full","pubTime":"2026-09-24 17:07","pubTimestamp":1790240820,"startTime":"0","endTime":"0","summary":"9月24日，泰德医药（03880）发布公告，宣布公司已完成位于杭州市钱塘区的一处工业用地及房产的收购，作为其规模化多肽CDMO生产基地项目一期的建设用地。项目一期占地面积约30亩，现有厂房建筑面积约1.35万平方米，预计将建设年产能为3-5吨的多肽原料药生产线。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609243883757855.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609243883757855.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1141","03880","CDMO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669046560","title":"泰德医药：完成收购杭州一处工业用地及房产 拟作多肽定制研发生产基地","url":"https://stock-news.laohu8.com/highlight/detail?id=2669046560","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669046560?lang=zh_cn&edition=full","pubTime":"2026-09-24 17:00","pubTimestamp":1790240450,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["03880","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186085289","title":"泰德医药（03880.HK）更新董事会及委员会成员组成","url":"https://stock-news.laohu8.com/highlight/detail?id=1186085289","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1186085289?lang=zh_cn&edition=full","pubTime":"2026-09-24 16:54","pubTimestamp":1790240081,"startTime":"0","endTime":"0","summary":"2026年9月24日，泰德医药公布最新董事会及其下属委员会成员名单及职能分工。公司表示，本次披露旨在让投资者及时了解公司治理架构的最新情况。以下为具体信息：。公告亦强调，上述成员分工符合公司章程及香港联交所相关规则要求。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03880"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179176680","title":"泰德医药03880收购杭州30亩工业用地　布局3-5吨级多肽CDMO产能","url":"https://stock-news.laohu8.com/highlight/detail?id=1179176680","media":"公告速递","labels":["corporation","merge","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1179176680?lang=zh_cn&edition=full","pubTime":"2026-09-24 16:54","pubTimestamp":1790240056,"startTime":"0","endTime":"0","summary":"泰德医药（浙江）股份有限公司9月24日发布自愿性公告称，公司已签署并完成位于杭州市钱塘区一处工业用地及房产的收购，拟将其作为集团规模化CDMO生产基地项目一期。该地块占地约30亩，现有厂房建筑面积约13,500平方米。公司计划在此建设规模化多肽原料药生产线，设计年产能预计3-5吨，实际产能及投产安排将取决于项目建设、设备调试、监管审批及市场需求等因素。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03880"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111424452","title":"泰德医药（03880）执行董事李玲梅辞任 自2026年9月24日起生效","url":"https://stock-news.laohu8.com/highlight/detail?id=1111424452","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1111424452?lang=zh_cn&edition=full","pubTime":"2026-09-24 16:51","pubTimestamp":1790239907,"startTime":"0","endTime":"0","summary":"泰德医药（03880）9月24日在港交所发布公告称，因个人工作安排，公司执行董事李玲梅已向董事会提出辞任，其辞任自2026年9月24日起生效。李玲梅确认，其与董事会并无意见分歧，且无任何事项需提请股东或香港联合交易所有限公司注意。\n董事会向李玲梅在任职期间对公司的贡献表示感谢。\n公告同时披露，截至公告日期，公司董事会成员构成为：执行董事徐琪、李湘、李湘莉及Cheng Tao；非执行董事吴一暉；独立非执行董事于常海、朱迅及夏心晟。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03880"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669046584","title":"泰德医药(03880.HK)已收购杭州市的物业作为集团规模化CDMO生产基地项目一期项目","url":"https://stock-news.laohu8.com/highlight/detail?id=2669046584","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669046584?lang=zh_cn&edition=full","pubTime":"2026-09-24 16:51","pubTimestamp":1790239872,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["03913","03880","BK1542","BK1229","BK1141","BK1258"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669463712","title":"泰德医药(03880)：李玲梅已辞任执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2669463712","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669463712?lang=zh_cn&edition=full","pubTime":"2026-09-24 16:46","pubTimestamp":1790239564,"startTime":"0","endTime":"0","summary":"智通财经APP讯，泰德医药(03880)发布公告，李玲梅女士(李女士)因个人工作安排，已辞任执行董事，自2026年9月24日起生效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1500460.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"泰德医药(03880)：李玲梅已辞任执行董事","news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1141","03880"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106082964","title":"泰德医药2026年中期财报：营收2.35亿元，经调整净利润0.56亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1106082964","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1106082964?lang=zh_cn&edition=full","pubTime":"2026-09-24 16:41","pubTimestamp":1790239276,"startTime":"0","endTime":"0","summary":"泰德医药公布了2026年中期业绩，报告期内实现营收2.35亿元，同比下降7.6%。经调整净利润0.56亿元，同比下降46.4%。毛利率由上年同期的61.1%下降至58.0%。经营活动所产生的现金流净额约为0.39亿元，对比上年同期的1.83亿元减少78.9%。从成本结构来看，销售及营销费用约1,880万元，同比增长1.1%；管理费用约2,930万元，同比减少27.7%；研发投入约1,680万元，同比增长32.5%，占总营收比例约为7.2%。管理层预期下半年收入将逐步回升，并对公司未来的长期发展及核心业务保持信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"泰德医药2026年中期财报：营收2.35亿元，经调整净利润0.56亿元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03880"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179864906","title":"泰德医药8月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1179864906","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1179864906?lang=zh_cn&edition=full","pubTime":"2026-09-03 16:51","pubTimestamp":1788425517,"startTime":"0","endTime":"0","summary":"泰德医药（浙江）股份有限公司（股票代码：03880）于2026年9月3日披露2026年8月股份变动月报。公告显示，截至8月31日，公司已发行普通股（H股）总数为141,800,000股，注册资本为人民币141,800,000元。报告期内未有新增发行、回购、注销或库藏股活动，股本结构维持不变。\n公司表示，公告由公司秘书陈祯签署，并确认已遵守香港联交所《上市规则》及相关法律法规的要求。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03880"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127273008","title":"泰德医药（03880）拟系统优化治理结构　多项章程及制度修订待临时股东大会表决","url":"https://stock-news.laohu8.com/highlight/detail?id=1127273008","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1127273008?lang=zh_cn&edition=full","pubTime":"2026-08-27 16:52","pubTimestamp":1787820759,"startTime":"0","endTime":"0","summary":"泰德医药（浙江）股份有限公司8月27日公告称，董事会已审议通过多项治理文件修订议案，涵盖公司章程、股东会议事规则、董事会议事规则，以及独立非执行董事工作制度和对外担保管理制度。相关修订尚需提交即将召开的临时股东大会表决，其中修订公司章程、股东会议事规则和董事会议事规则须以特别决议案形式获股东批准，其余制度修订以普通决议案表决。临时股东大会具体日期及议程将通过通函形式另行通知全体股东。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03880"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662774456","title":"泰德医药(03880)建议采纳受限制股份单位计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2662774456","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662774456?lang=zh_cn&edition=full","pubTime":"2026-08-27 16:45","pubTimestamp":1787820310,"startTime":"0","endTime":"0","summary":"智通财经APP讯，泰德医药 发布公告，于2026年8月27日，董事会通过决议，内容有关建议采纳受限制股份单位计划;及建议采纳服务提供者分项限额。鉴于合资格参与者的范围扩大至包括服务提供者，董事会认为，根据上市规则第17.03A条的规定，在计划授权限额内采纳服务提供者分项限额属适当。因此，根据受限制股份单位计划不时授予服务提供者的奖励总数，不得超过截至采纳日期已发行股份总数的1%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1486927.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1141","03880"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142629147","title":"泰德医药2026年上半年营收2.35亿元，经调整净利润0.56亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1142629147","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1142629147?lang=zh_cn&edition=full","pubTime":"2026-08-27 16:38","pubTimestamp":1787819918,"startTime":"0","endTime":"0","summary":"泰德医药公布截至2026年6月30日止上半年财报，报告期内实现营收2.35亿元，同比下降7.6%。期内毛利率为58.0%，同比下降3.1个百分点。经调整净利润为0.56亿元，同比下降46.4%。成本方面，报告期内销售成本约0.99亿元，同比下降0.3%。CRO业务收入达到0.65亿元，同比增长17.8%。CDMO业务则录得1.69亿元，同比下降14.7%。其中，按不同服务模式划分，FFS业务收入约2.10亿元，同比下降10.0%；FTE业务收入0.25亿元，同比增长18.9%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"泰德医药2026年上半年营收2.35亿元，经调整净利润0.56亿元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03880"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100593776","title":"泰德医药（03880）拟推出受限制股份单位计划 规模上限占股本10%","url":"https://stock-news.laohu8.com/highlight/detail?id=1100593776","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1100593776?lang=zh_cn&edition=full","pubTime":"2026-08-27 16:38","pubTimestamp":1787819884,"startTime":"0","endTime":"0","summary":"2026年8月27日，泰德医药公告称，公司董事会当日通过决议，拟于临时股东大会上提请股东审议并批准两项议案：一是《2026年泰德医药受限制股份单位计划》；二是“服务提供者分项限额”的设立。因RSU计划发行的新H股须获香港联交所上市及买卖批准。公司表示，如未来需调整服务提供者分项限额，将另行提交股东大会审议。公告最后提醒，RSU计划及服务提供者分项限额的特别决议案均需在即将召开的临时股东大会上表决通过后方可实施。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03880"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662977484","title":"泰德医药(03880)公布中期业绩 净利润约5367.7万元 同比减少47.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662977484","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662977484?lang=zh_cn&edition=full","pubTime":"2026-08-27 16:35","pubTimestamp":1787819722,"startTime":"0","endTime":"0","summary":"智通财经APP讯，泰德医药 公布2026年中期业绩，收益约2.35亿元，同比减少7.6%;毛利约1.36亿元，同比减少12.3%;净利润约5367.7万元，同比减少47.4%。上半年，该集团继续积极扩充其钱塘及罗克林园区的多肽产能。同时，罗克林园区的翻新及设备安装工程正按计划推进。截至2026年6月30日止六个月，资本开支增加至9890万元，反映集团持续的产能扩充举措。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1486909.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03880"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660348657","title":"泰德医药(03880.HK)拟8月27日举行董事会会议以审批中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2660348657","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660348657?lang=zh_cn&edition=full","pubTime":"2026-08-17 17:17","pubTimestamp":1786958230,"startTime":"0","endTime":"0","summary":"格隆汇8月17日丨泰德医药(03880.HK)公告，董事会会议将于2026年8月27日(星期四)召开，藉以(其中包括)审议及批准公司及其附属公司截至2026年6月30日止6个月的中期业绩及其刊发。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260817/32337228.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["03880","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162717331","title":"泰德医药(03880)拟于2026年8月27日召开董事会审议2026年中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1162717331","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1162717331?lang=zh_cn&edition=full","pubTime":"2026-08-17 16:36","pubTimestamp":1786955818,"startTime":"0","endTime":"0","summary":"泰德医药（浙江）股份有限公司（03880）8月17日公告称，公司董事会计划于2026年8月27日（星期四）召开会议，届时将审议并批准公司及其附属公司截至2026年6月30日止六个月的中期业绩及其发布事宜。  \n  \n公告显示，董事会现由执行董事徐琪博士（兼董事长兼首席执行官）、李湘博士、李湘莉女士、Cheng Tao女士及李玲梅女士；非执行董事吴一晖先生；以及独立非执行董事于常海博士、朱迅博士、夏心晟先生组成。  \n  \n公司未在公告中披露任何财务数据。待董事会审议通过后，相关中期业绩将另行发布。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03880"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657698357","title":"港股CXO近日股价集体走高，盈警之后的泰德医药(03880)将逆市下跌还是超跌反弹？","url":"https://stock-news.laohu8.com/highlight/detail?id=2657698357","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657698357?lang=zh_cn&edition=full","pubTime":"2026-08-07 10:22","pubTimestamp":1786069332,"startTime":"0","endTime":"0","summary":"7月31日盘后，泰德医药发布了其26H1财年盈警公告。目前泰德医药尚未迎来连续数个交易日的低点逐步抬高以彻底终结下跌趋势，关键的量能均线也尚未出现明显转折。近日，港股医药概念股集体走高，CXO、创新药板块多点爆发，带动恒生医疗保健指数强势反弹。以8月4日行情为例，港股CXO板块出现一波个股集体走高，其中药明康德股价大涨11.17%，康龙化成和泰格医药均涨超5%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1477144.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["CXO","03880","BK4585","KCAI","NIFE","BK1141","VXUS","WX","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169061968","title":"泰德医药7月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1169061968","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1169061968?lang=zh_cn&edition=full","pubTime":"2026-08-05 16:51","pubTimestamp":1785919909,"startTime":"0","endTime":"0","summary":"泰德医药（浙江）股份有限公司于2026年8月5日发布2026年7月股份变动月报表，报告期为截至2026年7月31日。公告显示，公司普通股H股的已发行股本数量和注册股本在报告期内均维持不变。报告期内，公司无新增发行、购回、注销或库藏股活动，已发行股份及库存股份数目稳定在141,800,000股和0股，符合香港联合交易所有限公司关于最低公众持股量的相关规定。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03880"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655562893","title":"泰德医药(03880)成功完成HEPCLUDEX®原料药之美国FDA上市许可前检查(PLI)","url":"https://stock-news.laohu8.com/highlight/detail?id=2655562893","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655562893?lang=zh_cn&edition=full","pubTime":"2026-07-31 16:39","pubTimestamp":1785487145,"startTime":"0","endTime":"0","summary":"智通财经APP讯，泰德医药 发布公告，公司全资附属公司中肽生化有限公司位于中国杭州的现行生产质量管理规范生产设施，已成功通过由美国食品及药物管理局开展的上市许可前检查。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1474593.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LABU","BK1141","03880","BK4588","BK4585","IPOS"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.medtideinc.com","stockEarnings":[{"period":"1week","weight":0.0204},{"period":"1month","weight":0.1344},{"period":"3month","weight":-0.1385},{"period":"6month","weight":-0.0566},{"period":"1year","weight":-0.3131},{"period":"ytd","weight":-0.3104}],"compareEarnings":[{"period":"1week","weight":0.0027},{"period":"1month","weight":-0.0186},{"period":"3month","weight":-0.0136},{"period":"6month","weight":-0.0776},{"period":"1year","weight":-0.0596},{"period":"ytd","weight":-0.0501}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"泰德医药（浙江）股份有限公司是一家主要从事多肽的合约研究、开发和生产的中国公司。该公司主要提供合约研究机构（CRO）服务，即多肽新化学实体（NCE）发现合成、合约开发及生产机构（CDMO）服务即多肽化学、制造及控制（CMC）开发以及商业化生产。该公司的服务主要专注于向客户提供活性药物成分（APIs），而非药品。该公司也为客户提供多肽类药物开发、生产、CMC申报支持服务。该公司主要在国内市场和海外市场开展业务。","exchange":"SEHK","name":"泰德医药","nameEN":"MEDTIDE"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"泰德医药(03880)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供泰德医药(03880)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"泰德医药,03880,泰德医药股票,泰德医药股票老虎,泰德医药股票老虎国际,泰德医药行情,泰德医药股票行情,泰德医药股价,泰德医药股市,泰德医药股票价格,泰德医药股票交易,泰德医药股票购买,泰德医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"泰德医药(03880)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供泰德医药(03880)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}